New drugs for the management of lung cancer

Hospital Medicine

Volumn 55, Issue 10, 1996, Pages 634-638

  Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DNA TOPOISOMERASE;

DRUG ANTAGONISM; HUMAN; LUNG TUMOR; REVIEW; SMALL CELL CARCINOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; DNA TOPOISOMERASES, TYPE I; HUMANS; LUNG NEOPLASMS;

EID: 0030585144     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Haking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer, a phase II study. J Clin Oncol 12: 1535-40
2. Anderson H, Lund B, Bach F, Thatcher N, Walling T, Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer, a phase II study. J Clin Oncol 12: 1821-6
3. Ardizzoni A, Hansen H, Dombernowsky P et al (1994) Phase II study of topotecan in pretreated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 13: 336
4. Cerny T, Kaplan S, Pavlidis N et al (1994) Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials group (ECTG). Br J Cancer 70: 384-7
5. Chang AY, Kim K, Glik J et al (1993) Phase II study of taxol, merbarone and piroxantrone in stage IV non small cell lung cancer: the Eastern Cooperative Oncology Group experience. J Natl Cancer Inst 85: 388-94
6. Choy H, Akerley W, Safran H et al (1994) Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12: 2682-6
7. Cormier Y, Eisenhauer E, Muldal A et al (1994) Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). Ann Oncol 5: 283-5
8. Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13: 2643-55
9. Crino L, Scagliotti G, Marangolo M et al (1995) Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC), a phase II study. Proc Am Soc Clin Oncol 14: 352
10. Depierre A, Lemarie E, Dabouis G et al (1991) A phase II study of navelbine (Vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 14: 115-19
11. Depierre A, Chastang Cl. Quiox E et al (1994) Vinorelbine vs vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 5: 37-42
12. Einhorn LW, Pennington K, McClean J (1990) Phase II trial of daily oral VP-16 in refractory small cell lung cancer. A Hoosier Oncology Group study. Semin Oncol 17:32-5
13. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al (1994) European-Canadian trial of paclitaxel in relapsea ovarian cancer: high-dose vs low-dose and long vs short infusion. J Clin Oncol 12: 2654-66
14. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13: 1430-5
15. Fossella FV, Lee JS, Murphy WK, et al (1994) Phase II study of docetaxel lor recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12: 1238-14
16. Fossella FV, Lee JS, Shin DM et al (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13: 645-51
17. Francis PA, Rigas TR, Kris MG et al (1994) Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232-7
18. Fukuoka M, Nitam H, Susuki A et al (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10:16-20
19. Gatzemeier U, Heckmayr M, Neuhauss R et al (1995) Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 12(Suppl 2): S101-6
20. Hainsworth ID, Thompson DS, Greco FA (1995) Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13: 1609-14
21. Jassem J, Karnika-Mlodkowska H, van Pottelsberghe C et al (1993) Phase II study of vinorelbine (navelbine) in previously treated small cell lung cancer. Eur J Cancer 29A: 1720-2
22. Kudo S, Hino M, Fujita A et al (1994) Late phase II clinical study of RP 56976 (docetaxel) in patients with non-small cell lung cancer. Jap J Cancer Chemother 21: 2617-23
23. Langer CJ, Leighton JC, Comis RL et al (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analy-sis. J Clin Oncol 13:1860-70
24. Le Chevalier T, Brisgand D, Douillard JY et al (1994) Randomized study of vinorelbine and cisplatin vs vindesine and cisplatin vs vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-7
25. Lee JS, Libshitz HI, Murphy WK et al (1990) Phase II study of 10-ethyl-10-deaza-aminopterin (10-EDAM; CGP 30694) for stage IIIB or IV non-small cell lung cancer. Invest New Drugs 8: 299-304
26. Lee JS, Libshitz HI, Fossella FV et al (1992) Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small cell lung cancer. J Natl Cancer Inst 84: 1039-40
27. Lynch TJ, Kalish L, Strauss G et al (1994) Phase II study of topotecan in metastatic non-small cell lung cancer. J Clin Oncol 12: 347-52
28. Masuda N, Fukuoka M, Takada M et al (1992a) CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol 10: 1775-80
29. Masuda N, Fukuoka M, Kusunoki Y et al (1992b) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225-9
30. Masuda N, Fukuoka M, Kudoh S et al (1994a) Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support For advanced non-small-cell lung cancer. J Clin Oncol 12: 90-6
31. Masuda N, Fukuoka M, Kudoh S et al (1994b) Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 12: 1833-41
32. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75: 968-72
33. Millward MJ, Bishop JF, Friedlander M et al (1996) Phase II trial trial or a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 14: 142-8
34. Murphy WK, Fossella FV, Winn RJ et al (1993) Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85: 384-8
35. Perez-Soler R, Fossella FV, Glisson BS et al (1996) Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated by chemotherapy. J Clin Oncol 14: 503-13
36. Schiller JH, Kim K, Johnson D (1994) Phase II study of topotecan in extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 13: 330
37. Shinkai T, Arioka H, Kunikane H et al (1994) Phase I clinical trial of irinotecan (CPT-11), 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res 54: 2636-42
38. Shum KY, Kris MG, Gralla RJ et al (1988) Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 6: 446-50
39. Slevin ML, Clark PI, Joel SP et al (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7: 1333-40
40. Smyth JF, Smith IE, Sessa C et al (1994) Activity of docetaxel (taxotere) in small cell lung cancer. Eur J Cancer 30A: 1058-60
41. Sorenson JB (1995) Gemcitabine in non-small cell lung cancer. Lung Cancer 12(Suppl 1): S173-5
42. Souhami RL, Rudd RM, Spiro SG et al (1992) Phase II study of edatrexate in stage III and IV non-small cell lung cancer. Cancer Chemother Pharmacol 30: 465-8
43. Stewart LA, Pignon JP, for the Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899-909
44. Vokes EE, Rosemberg RK, Jahanzeb M et al (1995) Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. J Clin Oncol 13: 637-44
45. Waits TM, Johnson DH, Hainsworth JD et al (1992) Prolonged administration of oral etoposide in non-small cell lung cancer. A phase II trial. J Clin Oncol 10: 292-6